Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Prime Medicine, Inc.NASDAQ: PRME
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -5738.6%
Net margin was -5738.6% in Q1 FY2026, down 2169.8 pp from a year earlier. On a trailing-twelve-month basis it was -4917.6%, up 334.9 pp year over year.
What to watch
Whether net margin reaches the consensus estimate from 8 analysts of -1307.5% for the fiscal year ending Dec 2026, up from -4342.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -5738.6%-239.9 pp QoQ
- Last fiscal yearDec 2025
- -4342.4%+2224.2 pp YoY
- LTMMar 2026
- -4917.6%+334.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2169.8 pp | +2684.4 pp | +4854.2 pp |
| 1 year | +2224.2 pp | +3034.9 pp | +810.7 pp |
| 3 years | — | +3822.8 pp | — |
| 5 years | +4240.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -4342.4%
- Year-over-year change
- +2224.2pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -4342.4% | +2224.2pp |
| FY2024 | 2024-12-31 | -6566.6% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Net Margin vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's LTM Mar 2026 net margin of -4917.6% is the lowest of the 6 companies compared; the peer median is -597.0%.
- Its year-over-year change of +334.9 pp is the 4th highest of 6, against a peer median of +419.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | -54.7% | +606.6 pp | +417.3 pp | |
| LTM Mar 2026 | -281.6% | +419.5 pp | +723.2 pp | |
| LTM Mar 2026 | -597.0% | +557.1 pp | +299.9 pp | |
| LTM Mar 2026 | -1189.1% | +301.7 pp | -609.6 pp | |
| LTM Sep 2026 | -1812.1% | -515.0 pp | +132552.9 pp | |
| LTM Mar 2026 | -4917.6% | +334.9 pp | — | |
| FY2025 | — | — | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — |
| Peer median (excluding PRME) | -597.0% | +419.5 pp | +417.3 pp | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.98M | 4.63M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 7.32M |
| Gross Profit | 0 | 0 | 0 | 2.98M | (2.69M) |
| Gross Margin | — | — | — | 100.0% | -58.1% |
| Research & Development | 70.55M | 86.73M | 147.91M | 155.29M | 160.64M |
| Selling, General & Admin | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M |
| Operating Expenses | 84.47M | 116.54M | 204.79M | 205.45M | 205.66M |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| EBITDA | (165.29M) | (120.55M) | (186.64M) | (189.75M) | (195.76M) |
| EBITDA Margin | — | — | — | -6361.2% | -4226.2% |
| Operating Income | (84.47M) | (116.54M) | (204.79M) | (202.47M) | (208.35M) |
| Operating Margin | — | — | — | -6787.4% | -4498.1% |
| Interest Income | 0 | 0 | 0 | 3.52M | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (81.38M) | (6.23M) | 6.38M | 6.59M | 7.21M |
| Income Before Tax | (165.85M) | (122.77M) | (198.41M) | (195.88M) | (201.14M) |
| Pre-Tax Margin | — | — | — | -6566.6% | -4342.4% |
| Income Tax Expense | (486K) | (948K) | (279K) | 0 | 0 |
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Net Margin | — | — | — | -6566.6% | -4342.4% |
| EPS (Basic) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| EPS (Diluted) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| Weighted Avg Shares | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
| Weighted Avg Shares (Diluted) | 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.